# Cancer-associated HIF-2α impacts trunk neural crest stemness

Sofie Mohlin[a,b,c*], Camilla U. Persson[b,1], Elina Fredlund[a,b,1], Emanuela Monni[d,e], Jessica M. Lindvall[f], Zaal Kokaia[d,e], Emma Hammarlund[b] and Marianne E. Bronner[c]

[a] Division of Pediatrics, Department of Clinical Sciences, Lund University, Lund, Sweden.

[b] Translational Cancer Research, Lund University Cancer Center at Medicon Village, Lund University, Lund, Sweden.

[c] Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, 91125, USA.

[d] Laboratory of Stem Cells and Restorative Neurology, University Hospital, Lund, Sweden.

[e] Lund Stem Cell Center, Lund University, Lund, Sweden.

[f] Jessica M. Lindvall, National Bioinformatics Infrastructure Sweden (NBIS), Science for Life Laboratory, Department of Biochemistry and Biophysics, Stockholm University, S-10691 Stockholm, Sweden.

[1]These authors contributed equally to this work

[*]Correspondence to: Sofie Mohlin; sofie.mohlin@med.lu.se. Translational Cancer Research; Division of Pediatrics, Lund University Cancer Center, Lund, Sweden.

## Abstract

The neural crest is a stem cell population that gives rise to sympathetic ganglia, the cell type of origin of neuroblastoma. Hypoxia Inducible Factor (HIF)-2α is associated with high risk neuroblastoma, however, little is known about its role in normal neural crest development. To address this important question, here we show that HIF-2α is expressed in trunk neural crest cells of human, murine and avian embryos. Modulating HIF-2α *in vivo* not only causes developmental delays but also induces proliferation and stemness of neural crest cells while altering the number of cells migrating ventrally to sympathoadrenal sites. Transcriptome changes after loss of HIF-2α reflect the *in vivo* phenotype. The results suggest that expression levels of HIF-2α must be strictly controlled and abnormal levels increase stemness and may promote metastasis. Our findings help elucidate the role of HIF-2α during normal development with implications also in tumor initiation at the onset of neuroblastoma.

**Key words**: Neural crest, trunk neural crest, neuroblastoma, hypoxia inducible factor-2, HIF, chick embryo

## Introduction

The neural crest is a multipotent stem cell population that is unique to vertebrate embryos. Originating from the ectodermal germ layer, premigratory neural crest cells arise in the dorsal neural tube during neurulation and are characterized by expression of transcription factors like *FOXD3*, *TFAP2* and *SOXE* (Khudyakov & Bronner-Fraser, 2009). Neural crest cells subsequently undergo an epithelial-to-mesenchymal transition (EMT) to delaminate from the neuroepithelium, then migrate extensively throughout the embryo, populating distant sites. Upon reaching their final destinations, neural crest cells form a large variety of cell types, as diverse as elements of the craniofacial skeleton, melanocytes of the skin, adrenal chromaffin cells and sympathetic neurons and glia (Ayer-Le Lievre & Le Douarin, 1982; Bittencourt, da Costa, Calloni, Alvarez-Silva, & Trentin, 2013; Bronner-Fraser & Fraser, 1988; Vega-Lopez, Cerrizuela, Tribulo, & Aybar, 2018).

The stem cell properties and migratory nature of the neural crest are highly reminiscent of tumor cells. Indeed, many of the genes involved in neural crest EMT are redeployed in metastatic cancers including many types of neural crest-derived cancers. Thus, neural crest cells represent an excellent model for studying the origin of neural crest-derived tumors including pediatric neuroblastoma, a tumor of infancy responsible for 15% of all cancer-related deaths in children (Maris, 2010). Neuroblastoma patients are very young, with some tumors detected in newborns. It is well accepted that neuroblastoma derives from sympathetic neuroblasts that originate from trunk neural crest cells (De Preter et al., 2006; Hoehner et al., 1996).

High risk neuroblastoma correlates with the presence of cells in perivascular niches (Pietras et al., 2008) that express high levels of Hypoxia Inducible Factor (HIF)-2α together with numerous neural crest markers (Holmquist-Mengelbier et al., 2006; Pietras et al., 2008; Pietras

et al., 2009). Under normal conditions, HIF-2α is stabilized at low oxygen levels and responds to hypoxia by initiating a transcriptional program for cellular adaptation to changes in metabolic demand. In neuroblastoma, however, HIF-2α becomes abnormally stabilized at physiological oxygen tensions (~5% $O_2$) (Holmquist-Mengelbier et al., 2006). This, together with the presence of neural crest markers in neuroblastoma tumors, raises the intriguing possibility that HIF-2α expressing neural crest cells in the early embryo might reflect the cell type of origin in tumor initiation.

Here, we explore this possibility by examining the role of HIF-2α, encoded by the gene *EPAS1,* during normal neural crest development and possible correlations with neuroblastoma. We show that HIF-2α is expressed in migrating trunk neural crest and sympathetic neuroblasts in human, murine and avian embryos. RNA sequencing of trunk neural crest cells with dysregulated HIF-2α levels demonstrates a shift in the global transcriptional program, resulting in enrichment in genes associated with processes connected to tumor morphology, invasion, EMT and arrested embryo growth. Perturbation experiments in chick embryos *in vivo* result in a delay in embryonic growth, altered expression of trunk neural crest genes, and disrupted trunk neural crest cell migration. Consistent with this, *in vitro* crestospheres display increased proliferation and self-renewal capacity. The results suggest that expression levels of HIF-2α must be tightly regulated. These findings enhance our understanding of how genes dysregulated in normal development may result in onset of neuroblastoma.

## Results

### *HIF-2α is expressed in migratory trunk neural crest cells in chick embryos*

The presence of neuroblastoma cells expressing hypoxia inducible factor (HIF)-2α in perivascular tumor niches indicates poor prognosis in this tumor form. That these cells express stem cell- and neural crest associated proteins raises the intriguing possibility that they may constitute a tumor-initiating subpopulation of cells that resembles embryonic neural crest cells. HIF-2α is a transcription factor that localizes to the nucleus but also is found in the cytoplasm (Holmquist-Mengelbier et al., 2006; Mohlin, Hamidian, & Pahlman, 2013), though its role in the cytoplasm remains unknown. Consistent with this dual localization, Western blots of stage HH18 wild type chick embryos revealed expression of HIF-2α in both the nuclear and cytoplasmic fractions (**Figure 1A**), similar to what has been observed in oxygenated neuroblastoma cells (Holmquist-Mengelbier et al., 2006).

As a first step in exploring the role of HIF-2α in the embryo, we examined its spatiotemporal expression during normal neural crest development. To this end, RNA was extracted from whole chick embryos from stages HH4 to HH27, reflecting stages from gastrulation to mid-gestation. The results revealed continuous expression of HIF-2α (encoded by the gene *EPAS1*) over the time course analyzed, with a peak at HH18 which reflects the time of active trunk neural crest migration (**Figure 1B**). Next, we performed immunocytochemistry with an antibody against HIF-2α in transverse sections through the trunk region of stage HH11, HH13 and HH18 embryos. We detected HIF-2α protein in scattered neural crest cells within the neural tube of HH11 and HH13 embryos, stages when trunk neural crest cells are still premigratory (**Figure 1C-D**, respectively). We further detected HIF-2α in trunk neural crest cells that had delaminated from the neural tube and initiated migration (**Figure 1E-F**). Possible non-specific binding by the primary antibody was ruled out by secondary antibody only staining

(**Supplementary Figure S1A**).

HIF-2α is canonically induced at low oxygen levels. To understand variations in oxygen consumption during the developmental stages of interest, we measured $O_2$ saturation in real-time in the developing chick embryo utilizing a microsensor technique (**Figure 1G**). Within the trunk neural tube, oxygen saturation starts out high (up to 85% ± 5 SEM $O_2$ saturation) at premigratory to migratory stages of neural crest development (HH10 – HH16) and gradually decreases (**Figure 1G**). At the time when the majority of trunk neural crest cells have delaminated from the tube (HH18), oxygen saturation is low (23% ± 10 SEM $O_2$ saturation), only to rise at later time points (**Figure 1G**). Together with the expression data above, the results suggest that HIF-2α is independent of oxygen availability in the developing embryo (**Figure 1C-G** and **Figure 2**).

*HIF-2α is expressed in sympathetic neuroblasts in human and mouse embryos*

*EPAS1* knockout mice have severe abnormalities in the sympathetic nervous system (Tian, Hammer, Matsumoto, Russell, & McKnight, 1998); consistent with this, there is some, albeit limited, data suggesting that HIF-2α is expressed in sympathetic chain ganglia up to murine day E11.5 (corresponding to human embryonic week 5). Moreover, mice lacking *PHD3* (HIF prolyl hydroxylase), a gene critical for regulation of HIF-2α, display reduced sympathetic nervous system (SNS) function that is rescued by crossing these mutants with $EPAS1^{+/-}$ mice (Bishop et al., 2008).

We have previously shown that HIF-2α is expressed in sympathetic ganglia of human embryos at embryonic week 6.5 (~E12.5 in mice) but that expression is lost in these cells at later stages (fetal week 8) (Mohlin et al., 2013). Here, we confirmed expression of HIF-2α in sympathetic ganglia in mouse embryos at E12.5 by staining adjacent sections with HIF-2α (**Figure 2A**) and TH (**Figure 2B**) antibodies, with the latter indicating the location of sympathetic ganglia. Demonstrating antibody specificity, HIF-2α expression was only observed in conventional neuroblastoma SK-N-BE(2)c cells cultured at hypoxia (1% $O_2$) but not normoxia (21% $O_2$) (**Supplementary Figure S1B**). In sections, we detected HIF-2α positive cells specifically in the dorsal neural tube, as well as in early neural crest migratory streams in sections through the trunk region of a human embryo of embryonic week ew5 (Carnegie stage 13; **Figure 2C-D**). In contrast, there were virtually no HIF-2α positive cells left within the neural tube at embryonic week ew6 (Carnegie stage 16). Rather, positive cells could be detected migrating along the ventral pathway followed by sympathoadrenal precursors (**Figure 2E**). Consistent with our biochemical analysis in the chick (**Figure 1A**), human HIF-2α expression was noted in both the nucleus and cytoplasm (**Figure 2E**).

*Knockdown of HIF-2α delays embryogenesis, alters gene expression and affects cell numbers along the ventral neural crest migratory pathway*

To examine the role of HIF-2α *in vivo*, we performed loss-of-function experiments in chick embryos using both morpholino-mediated knock-down as well as CRISPR/Cas9 knock-out using three different gRNAs. We then let the embryos develop for an additional one (for gene expression) or two (for staging and migration) days and analyzed several potentially affected biological processes. Surprisingly, we noticed that HIF-2α knockdown embryos were

154 developmentally delayed compared with their control counterparts (**Figure 3A-D**). The stages
155 of embryos following CRISPR/Cas9- or morpholino mediated loss of HIF-2α were determined
156 by their Hamburger and Hamilton developmental stage *in ovo* **(Figure 3A-B)** and by counting
157 somites *ex ovo* (**Figure 3C-D**).

158

159 Electroporation efficiency was confirmed by analyzing *EGFP* expression (**Supplementary**
160 **Figure S2A-B**). Knockdown of HIF-2α, either by morpholino or CRISPR/Cas9, led to
161 decreased expression levels of genes representative of early and migrating neural crest as well
162 as trunk neural crest cells in particular (Frith et al., 2018; Murko, Vieceli, & Bronner, 2018)
163 (**Figure 3E-G**, respectively, and **Supplementary Figure S2C-D**). In contrast, the cranial
164 neural crest associated gene *HOXA2* was not affected (**Figure 3F, H**).

165

166 One of the most important features of neural crest cells is their migratory ability. Trunk neural
167 crest cells destined to form the sympathetic chain ganglia migrate ventrally. After HIF-2α loss
168 of function using either morpholinos or CRISPR/Cas9, HNK1 positive migratory neural crest
169 cells were detected on the control side in all embryos (**Figure 4A-D**) as well as on the side
170 electroporated with non-targeting gRNA CTRL and control 5'-mismatch morpholino (**Figure**
171 **4A and 4C**, respectively). In contrast, loss of HIF-2α profoundly reduced the numbers of
172 HNK1 positive cells migrating to ventral regions of the embryo (CRISPR/Cas9, **Figure 4B**;
173 morpholino, **Figure 4D**).

174

175 SOX9, a member of the SoxE family of transcription factors, is important for neural crest fate.
176 It is expressed in premigratory neural crest cells at all axial levels and promotes their lineage

177 progression. Importantly, transverse sections through the trunk of embryos electroporated with
178 control or two different EPAS1 targeting gRNA constructs showed no differences in SOX9
179 expression (**Supplementary Figure S3A-C**), suggesting that neural crest lineage specification
180 was unaffected by loss of HIF-2α.

181

182 *Over-expression of HIF-2α has similar effects as loss-of-function*

183 Similar to the loss-of-function experiments, overexpression of HIF-2α led to delayed
184 embryonic development (**Figure 5A**) and perturbed migration as visualized by HNK1 staining
185 (**Figure 5B**). Expression of neural crest- and trunk specific genes was slightly suppressed
186 (**Figure 5C** and **Supplementary Figure S4A**) whereas expression of cranial neural crest gene
187 *HOXA2* was slightly induced (**Figure 5C**). Overexpression of *EPAS1* was confirmed by qRT-
188 PCR (**Supplementary Figure S4B**).

189

190 *Trunk neural crest cells proliferate extensively in response to dysregulated HIF-2α*

191 We next examined cell proliferation in premigratory and migrating neural crest cells after loss
192 of HIF-2α using real-time EdU pulse chase labeling optimized for avian embryos (Warren et
193 al., 2009). Quantifying the proportion of premigratory and early migrating neural crest cells
194 that had incorporated EdU demonstrated a significant induction of proliferating cells with an
195 average proportion of double positive cells of 22% and 70% in the 5'-mismatch versus EPAS1
196 morpholino targeted embryos, respectively (p 0.029; **Figure 6A-B**).

197

198 After over-expression of HIF-2α, real-time EdU incorporation demonstrated that cells with

increased expression of HIF-2α also became highly proliferative with an average proportion of double positive cells of 11% and 52% in the control and EPAS1 overexpressing embryos, respectively (p 0.011; **Figure 6C-D**). We conclude that neural crest proliferation is highly sensitive to expression levels of HIF-2α, suggesting that levels must be tightly controlled for proper development.

*HIF-2α downregulation enhances stem cell properties of trunk NC cells*

Neural crest-derived crestosphere cultures (Mohlin & Kerosuo, 2019; Mohlin, Kunttas, et al., 2019) enable studies on stemness properties of these cells *in vitro*. Therefore, we examined *EPAS1* expression in crestosphere cultures, in which multipotent neural crest cells can be maintained in a stem cell-like state *in vitro* (Kerosuo et al., 2015; Mohlin, Kunttas, et al., 2019). When comparing crestosphere cultures derived from trunk versus cranial axial levels, we noted that *EPAS1* was enriched in trunk crestospheres (**Figure 6E**). *In situ* hybridization further revealed two separate patterns of *EPAS1* expression in trunk crestospheres: equal distribution throughout the spheres or concentration in cells at the edges of the spheres (**Figure 6F**).

Next, we established trunk crestospheres from embryos electroporated with a control gRNA construct or two different gRNAs targeting *EPAS1*. Primary sphere assays demonstrated that cells with dysregulated HIF-2α levels had an increased ability to form new spheres when seeded as single cells (1 cell/well; **Figure 6G-H**). In addition, crestosphere cultures derived from embryos electroporated with the *EPAS1* targeting construct formed larger spheres compared to their control counterparts (**Figure 6H**).

*RNA-seq after loss of HIF-2α in neural crest cells identifies downstream genes associated with invasion, growth arrest and developmental regulation*

To investigate gene expression changes after loss of HIF-2α, we performed loss of function experiments at premigratory stages of neural crest development ($HH10^{+}$/HH11 in avian embryos) using a splice targeting morpholino as above. Neural tubes from trunk region were dissected 24 hours post-electroporation (at stage ~HH16) and subsequently analyzed by RNA sequencing. Correlation plot of all genes from the dataset demonstrated that trunk neural crest cells after knockdown of HIF-2α indeed differ from those injected with control scrambled morpholino (spearman $p>0.96$; **Figure 7A**). Setting a cut-off at $p<0.005$ and removing all hits that were not annotated (NA), we identified 97 genes of interest (**Figure 7B**). The top ten genes down- and upregulated (assessed by log2 fold differences in expression) by knockdown of HIF-2α are summarized in **Figure 7C**, while the complete list of these 97 genes can be found in **Supplementary Table S1**.

Gene set enrichment analysis (GSEA) on the RNA sequencing data described above demonstrated that two out of the top five processes connected to disease were cancer and tumor morphology (with 29 and 8 out of 97 molecules, respectively; **Figure 7D**). Deeper analysis of tumor morphology showed that genes associated with invasion of tumor cells and size and volume of tumor were particularly enriched, i.e. these associated genes linked to specific disease categories are not due to random chance but are statistically significant ($p<0.05$) (**Figure 7E**). Consistent with *in vivo* data, we identified cellular movement as one of the top molecular and cellular functions affected, with invasion as well as migration of tumor cells and epithelial-to-mesenchymal transition as predicted downstream pathways (**Figure 7E**). GSEA also revealed enrichment of genes associated with arrest in embryo growth (**Figure 7D-E**). We

conclude that the predicted cellular functions derived from our RNA sequencing experiment overlap with *in vivo* data (cf. **Figures 3-6**). Top networks from the RNA sequencing data showed enrichment of two signaling pathways, the ephrin receptor- and phosphatidylinositol 3-kinase (PI3K) signaling pathways (**Figure 7F** and **Supplementary Figure S5A**, with full list of gene ontology enriched processes in **Supplementary Table S2**).

Dividing the hits from RNA sequencing data that overlap with genes enriched for migration of tumor cells revealed a large subset of genes that encode for plasma membrane associated- or are secreted proteins (**Supplementary Figure S5B**). Several of these overlapping genes were among the 97 significantly differentially expressed (with cut-off $p<0.005$), suggesting a close regulatory relationship between HIF-2α and migration at least during these time points of development.

Given the effects we observed on embryonic development *in vivo*, we mapped potential upstream regulators of arrest in embryo growth. As expected, most genes were transcription factors, including *EPAS1* itself (**Figure 7G**). Among the predicted upstream regulators of arrested growth, genes associated with stem cells, BMP signaling and EMT were highly enriched (**Table 1** and **Supplementary Table S3**).

Two other predicted genes upstream of arrested embryo growth were *CDX2* and *HNF1B*, also among the 97 significantly (cut-off $p<0.005$) differentially expressed in the RNA sequencing data. Deeper analysis of these genes revealed autocrine signaling as well as an interconnected regulation between the two (**Supplementary Figure S5C**). EMT related genes *ZEB2* and

*SNAI1* are negatively regulated by both of these genes (**Supplementary Figure S5C**). In addition, *CDX2* was predicted to regulate *MYCN*, a transcription factor commonly amplified in aggressive neuroblastoma (**Supplementary Figure S5C**). Of the significantly (cut-off $p<0.005$) differentially expressed genes, *CDX2* and *HNF1B* were predicted to be upstream regulators of *EPAS1*. The majority of predicted *EPAS1* upstream regulators were transcription factors, and we observed an enrichment for stem cell associated genes (**Supplementary Table S4**).

*Trunk neural crest associated genes are enriched in neuroblastoma*

Neuroblastoma has long been recognized as derived from sympathetic neuroblasts of trunk neural crest based on marker expression and tumor localization (De Preter et al., 2006; Hoehner et al., 1996). However, recent studies from Adameyko and colleagues (Furlan et al., 2017; Kastriti et al., 2019; Soldatov et al., 2019) have raised questions regarding the origin of chromaffin cells as well as neuroblasts during embryonic development. While chromaffin cells mainly derive from Schwann cell precursors (Furlan et al., 2017), sympathetic neuroblasts are derived from sympathoadrenal precursor cells (Kastriti et al., 2019). Using a recently published dataset of migratory trunk neural crest enriched genes (Murko et al., 2018) as well as established neural crest and developmental markers, we examined connections between neuroblastoma and trunk neural crest cells. We compared expression of early neural crest marker *TFAP2B* as well as trunk neural crest markers *RASL11B*, *TAGLN3*, *NRCAM*, *AGPAT4*, *FMN2*, *HES5*, *HES6* (Murko et al., 2018) and *HOXC9* (Frith et al., 2018) in cancer cell lines of different origins (Cancer Cell Line Encyclopedia (CCLE) containing >600 cell lines; cancer types with $n\geq4$ cell lines were selected for further analysis (R2; http://hgserver1.amc.nl)) demonstrating enriched expression for the majority of these genes in neuroblastoma cells as compared to other cancer

293 types (**Figure 8A** and **Supplementary Figure S6A-C**). Cranial neural crest marker *HOXA2*
294 was on the other hand not enriched in neuroblastoma as compared to other cancer types
295 (**Supplementary Figure S6D**). Neuroblastoma patient-derived xenograft (PDX) cells have
296 been established from mouse models of orthotopic implantation of patient-derived tumor pieces
297 (Braekeveldt et al., 2015; Persson et al., 2017). These PDX cells retain characteristics of their
298 respective patient tumor and metastasize to clinically relevant sites *in vivo*. Real-time
299 quantitative PCR analyses demonstrated significant enrichment of neural crest (*TFAP2B*,
300 *SOX10*) and trunk neural crest (*RASL11B*, *FMN2*, *TAGLN3*, *NRCAM*, *HES6*, *HES5*, *AGPAT4*)
301 gene expression in neuroblastoma PDX cells as compared to cells from renal cell carcinoma
302 (RCC-4 and 786-0) and liver cancer cell lines (Hep3b) (**Figure 8B-C** and **Supplementary**
303 **Figure S6E**).

304

## Discussion

It has long been assumed that the childhood tumor form of neuroblastoma derives from sympathoadrenal neuroblasts. These assumptions have been based on the expression of proteins in neuroblastoma that are also expressed by embryonic sympathetic neurons during normal development, as well as the location where these tumors arise (i.e. along the sympathetic ganglia). HIF-2α has been implicated in tumor growth and is expressed in cancer stem cells of several tumors including neuroblastoma. However, little has been known about its expression and function during normal development. Here, we show that the HIF-2α protein is expressed in trunk neural crest cells and sympathetic neuroblasts during normal embryogenesis in three different species: human, mouse and avian and examine its function using the chick embryo as a model amenable to experimental manipulation. Comparable data across human, mouse and avian tissue suggest that cross-species interpretation of further results is valid.

Either knock-down or overexpression of HIF-2α in premigratory chick trunk neural crest affects several important functions. Not only do embryos with dysregulated HIF-2α have developmental delays compared to controls, but they also exhibit altered neural crest gene expression profiles. Consistent with observed *in vivo* effects, RNA sequencing demonstrates a global genome level change after loss of HIF-2α, with upregulation of genes involved in invasive behavior and growth arrest. Furthermore, we observed altered trunk neural crest migratory patterns as well as enhanced proliferative capacity of trunk neural crest cells *in vivo*, as well as in our RNA sequencing data.

Despite extensive proliferation of trunk neural crest cells with dysregulated HIF-2α expression,

328 the embryos as a whole develop at a slower pace than their control counterparts. In general, cell
329 division of trunk neural crest cells is limited during their active migratory phase. We speculate
330 that the observed embryonic delays relative to increased trunk neural crest cell proliferation
331 may be the result of a skewed cell division to migration ratio, with increased proliferation
332 perhaps causing a failure in cell migration.

333

334 The capacity to self-renew is an important feature of stem-like cells. Our data suggest that
335 *EPAS1* knockout cells exhibit enhanced self-renewal, in line with observations in
336 neuroblastoma cells with aberrant HIF-2α expression which are more immature and neural
337 crest-like (Pietras et al., 2008). In addition, crestospheres formed by HIF-2α dysregulated single
338 cells were larger, a sign of enhanced proliferative capacity in agreement with our EdU results.

339

340 The RNA sequencing data revealed enrichment of two signaling pathways, the ephrin receptor-
341 and PI3K pathways. This suggests that environmental cues may be influencing trunk neural
342 crest behavior. Of note, we have recently identified that PI3K-mTORC2 regulates HIF-2α
343 expression and functions as a valid treatment target in neuroblastoma (Mohlin et al., 2015;
344 Mohlin, Hansson, et al., 2019). Genes associated with migration of tumor cells mainly encode
345 for plasma membrane and secreted proteins, including several members of the matrix
346 metalloproteinase (MMP) family. MMPs promote invasion and migration by degrading
347 components of the extracellular matrix and have been shown to be regulated by HIF-2α in
348 several different tumor forms (Koh, Lemos, Liu, & Powis, 2011; Petrella, Lohi, & Brinckerhoff,
349 2005), further reinforcing a possible connection between HIF-2α, trunk neural crest cells and
350 invasive behavior.

The stem cell gene *POU5F1*, more commonly known as Oct4, is driven by HIF-2α in immature cells during development (Covello et al., 2006). We found that Oct4 is predicted to be upstream of arrested embryo growth, but also an upstream regulator of *EPAS1* itself. One of the *EPAS1* target molecules connecting Oct4 and HIF-2α is *CDX2*, which in turn is upstream of *EPAS1* as well as arrested embryo growth (**Supplementary Figure S5C**). CDX2 is indeed one of the major players involved in mediating the HIF-2α driven effects on embryonic development and considering that CDX2 is an early trunk neural crest marker (Frith et al., 2018), a possible explanation for delayed embryonic development might be halted trunk neural crest commitment.

These findings contribute to understanding of a complex regulatory network involved in mediating trunk neural crest development. We posit that the cancer associated protein HIF-2α may play a central role in embryonic growth, global gene expression, migration, proliferation and stem cell features of neural crest cells within this network (**Figure 8D**). Moreover, our results highlight the importance of careful regulation of HIF-2α levels for maintenance of normal embryonic growth and differentiation.

## Materials and Methods

*Chick embryo tissue*

According to Swedish regulations (Jordbruksverkets föreskrift L150, §5) work on chick embryos younger than embryonic day 13 do not require Institutional Animal Care and Use Committee oversight.

*Human and mouse fetal tissue*

Human fetal tissue (ethical approval Dnr 6.1.8-2887/2017, Lund University, Sweden) was obtained from elective abortions. Tissue samples were dissected in custom-made hibernation medium (Life Technologies) and fixed in 4% formaldehyde overnight. Following a sucrose gradient, embryos were embedded in gelatin for transverse sectioning at 12µm (ew5) or 7µm (ew6) using a cryostat.

*Embryos and perturbations*

Chick embryos were acquired from commercially purchased fertilized eggs and incubated at 37.5°C until desired developmental Hamburger Hamilton (HH) stages were reached (Hamburger & Hamilton, 1951). Optimal conditions for high transfection efficiency applying one-sided electroporation *in ovo* were determined to 5 pulses of 30ms each at 22V. Ringer's balanced salt solution (Solution-1: 144g NaCl, 4.5g $CaCl•2H_2O$, 7.4g KCl, $ddH_2O$ to 500ml; Solution-2: 4.35g $Na_2HPO_4•7H_2O$, 0.4g $KH_2PO_4$, $ddH_2O$ to 500ml (adjust final pH to 7.4)) containing 1% penicillin/streptomycin was used in all experiments. Morpholinos used were from GeneTools with the following sequences; splice targeting EPAS1 oligo (5'-GAAAGTGTGAGGGAACAAGTTACCT-3') and a corresponding 5'-mispair oligo (5'-GAtAcTGTcAGGcAACAAcTTACCT-3'). Morpholinos were injected at a concentration of 1mM and co-electroporated with a GFP tagged empty control vector (1 ug/ul). RFP-tagged

394 *EPAS1* overexpression construct and corresponding empty control vector were electroporated
395 at a concentration of 2.5 ug/ul. CRISPR constructs with gRNA non-targeting control (#99140,
396 Addgene) or gRNAs targeting *EPAS1* (EPAS1.1.gRNA Top oligo – 5'
397 ggatgGCTCAGAACTGCTCctacc 3', Bot oligo – 5' aaacggtagGAGCAGTTCTGAGCc 3';
398 EPAS1.2.gRNA Top oligo – 5' ggatgAAGGCATCCATAATGCGCC 3', Bot oligo – 5'
399 aaacGGCGCATTATGGATGCCTTc; 3'; EPAS1.3.gRNA Top oligo – 5'
400 ggatgAAATACATGGGTCTCACCC 3', Bot oligo – 5' aaacGGGTGAGACCCATGTATTTc
401 3') were cloned into U6.3>gRNA.f+e (#99139, Addgene) and electroporated at a concentration
402 of 1.5 ug/ul, and accompanying Cas9 (#99138, Addgene) at 2 ug/ul (Gandhi, Haeussler, Razy-
403 Krajka, Christiaen, & Stolfi, 2017). Embryos were allowed to sit at room temperature for 8 –
404 10 hours in order to allow the Cas9 protein to fold before further incubation of the embryos at
405 37.5°C.
406
407 For harvesting of trunk neural crest cells for RNA extraction, embryos were incubated at 37.5°C
408 for 24 (morpholinos and overexpression vectors) or 36 (CRISPR/Cas9) hours post-
409 electroporation. Embryos were incubated for 24 to 48 hours post-electroporation before
410 dissecting whole embryos for fixation and embedding.
411
412 *Cloning*
413 To overexpress HIF-2α, the gallus gallus *EPAS1* coding sequence was amplified using the
414 following primers; Fwd:
415 5'AAACTCGAGGCCACCATGGACTACAAAGACGATGACGACAAGGCAGGTATGAC
416 AGCTGACAAGGAGAAG-3', Rev 5'-AAAGCTAGCTCAGGTTGCCTGGTCCAG-3' and
417 cloned into the pCI H2B-RFP vector (Addgene plasmid #92398). For CRISPR/Cas9 targeting,
418 oligos designed to target *EPAS1* at three different locations (EPAS1.1, EPAS1.2 and EPAS1.3)

were annealed pairwise at a concentration of 100 µM per oligo using T4 DNA Ligase Buffer in $dH_2O$ by heating to 95°C for 5 minutes. The annealed oligo reactions were cooled to room temperature and diluted. The U6.3>gRNA.f+e (#99139, Addgene) vector was digested over night with BsaI-HF enzyme (New England Biolabs) and gel extracted. gRNAs were cloned into the digested U6.3>gRNA.f+e vector using T4 DNA Ligase (New England Biolabs) at room temperature for 20 minutes. Successful inserts were identified by colony PCR using U6 sequencing primer and gRNA reverse oligo specific to each *EPAS1* gRNA.

*Cell culture*

The human neuroblastoma cell line SK-N-BE(2)c (ATCC; Manassas, VA, US) and hepatocellular carcinoma cell line Hep3b (ATCC; Manassas, VA, US) were cultured in MEM while renal cell carcinoma RCC4 and 786-O cell lines were cultured in DMEM, supplemented with 10% fetal bovine serum and 100 units penicillin and 10µg/mL streptomycin. As part of our laboratory routines, all cells were maintained in culture for no more than 30 continuous passages and regularly screened for mycoplasma. SK-N-BE(2)c cells were authenticated by SNP profiling (Multiplexion, Germany).

*Neural tube dissection*

Neural tubes from respective axial levels were carefully dissected out from embryos at designated somite stages. For cranial-derived cultures, the very anterior tip was excluded, and the neural tube was dissected until the first somite level as previously described (Kerosuo, Nie, Bajpai, & Bronner, 2015). For trunk-derived cultures, the neural tube was dissected between somite 10-15 as previously described (Mohlin & Kerosuo, 2019; Mohlin, Kunttas, et al., 2019). Pools of neural tubes from 4 - 6 embryos were used for each culture.

443

444 *Crestosphere cell culture*

445 Neural tube derived cells were cultured in NC medium (DMEM with 4.5g/L glucose (Corning),
446 7.5% chick embryo extract (MP Biomedicals; Santa Ana, CA, USA), 1X B27 (Life
447 Technologies; Carlsbad, CA, US), basic fibroblast growth factor (bFGF, 20 ng/ml) (Peprotech;
448 Stockholm, Sweden), insulin growth factor -I (IGF-I, 20 ng/ml) (Sigma Aldrich; Darmstadt,
449 Germany), retinoic acid (RA; 60nM for cranial and 180nM for trunk, respectively) (Sigma
450 Aldrich; Darmstadt, Germany), and 25 ng/ml BMP-4 (for trunk) (Peprotech; Stockholm,
451 Sweden)) in low-adherence T25 tissue culture flasks as described previously (Mohlin &
452 Kerosuo, 2019; Mohlin, Kunttas, et al., 2019).

453

454 *Self-renewal assay*

455 Chick embryos at developmental HH stage 10+ were injected and electroporated with
456 CRISPR/Cas9 constructs and allowed to develop at 37.5°C to reach HH stage 13/14.
457 Crestosphere cultures were established from embryos electroporated with control, EPAS1.1 or
458 EPAS1.2 constructs, respectively. Crestospheres were dissociated into single cells using
459 Accutase (Sigma Aldrich; incubation at 37 °C for 40 min with one minute of pipetting every
460 10 min), and individual cells were manually picked using a p10 pipette tip under the
461 microscope. Single cells were transferred to 96-well plates prepared with 100 µl of NC medium
462 supplemented with retinoic acid and BMP-4 (Mohlin, Kunttas, et al., 2019). The absolute
463 number of spheres formed in each well was quantified manually under the microscope. Five
464 wells were analyzed per crestosphere culture. Sphere diameter was manually measured using
465 the ImageJ software (spheres measured n=33 and n=27 for CTRL and EPAS1.2, respectively).

*EdU pulse chase labelling*

Proliferation was measured using the Click-iT™ EdU Cell Proliferation kit (Invitrogen #C10337) according to the manufacturer's recommendations with optimizations from Warren et al (Warren, Puskarczyk, & Chapman, 2009). Chick embryos at developmental HH stage 10+ were injected and electroporated with morpholino or overexpression constructs and allowed to develop for additional 24 hours at 37.5°C. Eggs were then re-opened and EdU solution (500µM in PBS-DEPC) was added. Eggs were re-sealed and incubated at 37.5°C for another 4 hours before embryos were dissected in Ringer's solution and fixed in 4% paraformaldehyde overnight. Embryos were washed in PBS-DEPC, $H_2O$ and 3% BSA in PBS-DEPC before permeabilization in 0.5% Triton-X. Embryos were hybridized in reaction cocktail (Click-iT Reaction buffer, $CuSO_4$, Alexa Fluor 488 Azide and reaction buffer additive), washed and then DAPI stained. Embryos were after another round of washing processed through a sucrose gradient and embedded in gelatin.

*RNA sequencing*

Chick embryos of stage HH10+ were injected with EPAS1 targeting or corresponding 5'-mispair morpholinos in the lumen of the neural tube and subsequently electroporated for construct uptake. Following 24 hours of incubation at 37.5°C, embryos were removed from the eggs in Ringer's solution. Neural tubes from the trunk axial level of individual embryos were carefully dissected, removing surrounding mesodermal tissue, and transferred to Eppendorf tubes (neural tube tissue from one embryo per Eppendorf) that were snap frozen. RNA was extracted from each neural tube (5 samples per condition (EPAS1 and 5'-mispair, respectively)) using the RNAqueous Micro Kit (Ambion, #AM1931). Sequencing was performed using NextSeq 500 (Illumina). Alignment of reads was performed using the HISAT2 software and

the reference genome was from the Ensemble database (Gallus gallus 5.0). Expression counts were performed using the StringTie software and differentially expressed genes (DEG) analysis was performed using DESeq2. To obtain a relevant working list out of the 1105 significantly DEGs, we set a cut-off at $p<0.005$ and removed all hits that were not annotated (NA), ending up with 97 genes. Significance (p values) were DESeq2 derived (Love, Huber, & Anders, 2014). RNA sequencing data have been deposited in NCBI's Gene Expression Omnibus(Edgar, Domrachev, & Lash, 2002) and are accessible through GEO Series accession number GSE140319.

*Bioinformatics*

Gene Set Enrichment Analysis (GSEA) for gene ontology, network and functional analyses were generated through the use of Panther database (analyses performed autumn 2018; (http://pantherdb.org/) (Thomas et al., 2003) together with the Ingenuity Pathway Analysis (IPA) software(Kramer, Green, Pollard, & Tugendreich, 2014) (QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis). The use of the two databases/software contributed to an added biological value in terms of knowledge. For a hypothesis-free/exploratory analysis of the 97 DEGs, IPA was used (p-value calculations using right-tailed Fisher Exact Test). However, IPA was mainly used for deeper exploration of the data where the biological hypotheses generated for the project were further explored. Here, a hypotheses-driven approach was taken where the following categories found from the IPA analysis of the 97 DEGs were further investigated; "Cellular Movement", within the "Molecular and Cellular Function" result category, "Embryonic Development" , within the category "Physiological System Development and Function", and "Tumor Morphology" , within the "Disease and Disorders" category. These three biological networks were further

515 investigated within the data set at hand. The investigation for the possible overlap and
516 connections between these networks in the context of the data were hence explored.
517
518 *Whole mount in situ hybridization of crestospheres*
519 For whole mount *in situ* hybridization, crestospheres were fixed in 4% PFA for 30 minutes at
520 RT and washed in DEPC-PBT. Samples were gradually dehydrated by bringing them to 100%
521 MeOH and kept at -20°C until use. *In situ* hybridization was performed as previously described
522 (Acloque, Wilkinson, & Nieto, 2008). Crestospheres were rehydrated back to 100% PBT,
523 treated with Proteinase K/PBT, washed in 2 mg/ml glycine/PBT and post-fixed in 4%
524 paraformaldehyde / 0.2% glutaraldehyde for 20 minutes. Crestospheres were then
525 prehybridized in hybridization buffer for 2 hours at 70°C and hybridized with Digoxigenin
526 (DIG)-labeled EPAS1 probe overnight at 70°C. Crestospheres were washed in Wash solution I
527 and II (50% formamide, 1% SDS [Sodium Dodecyl Sulfate] and 5X SSC [NaCl and Na citrate]
528 or 2X SSC, respectively), and blocked in 10% Sheep Serum for 2 hours followed by incubation
529 with an anti-DIG antibody (1:2000) (Roche) in TBST / 1% sheep serum overnight at 4°C. On
530 day 3, embryos were washed in TBST throughout the day and overnight. Crestospheres were
531 washed in Alkaline phosphatase buffer (NTMT; 100mM NaCl, 100mM Tris-Cl (pH 9.5),
532 50mM MgCl2, 1%Tween-20) before visualizing the signal using 1-Step™ NBT/BCIP
533 Substrate Solution (ThermoFisher #34042). Stained crestospheres were fixed in 4% PFA for 20
534 minutes when they reached the desired state and dehydrated in MeOH to be stored at -20°C.
535 Embryos were embedded in blocks of gelatin for transverse sectioning at 20 µm using a
536 cryostat. Hybridization probe for avian *EPAS1* was prepared by using the following primers
537 (Forward 5'- CAAGGAGAAGAAGAGGAGCA -3'; Reverse 5'-
538 AAAGTGTGAGGAGGGCAAG -3') and chick embryo cDNA as template. The amplified

sequence was cloned into a pGEM-T Easy Vector before digestion and DIG RNA labeling (Roche #11277073910).

*Cryosections*

Fixed embryos and crestospheres were incubated in a sucrose gradient (5% sucrose for 10 minutes and 15% sucrose for 10 minutes up to several hours) followed by incubation in 7.5% gelatin over night at 37°C. Embedded samples were cryosectioned at 7, 10, 12 or 20 µm.

*Immunohistochemistry and immunofluorescence*

Immunohistochemistry on human (antigen retrieval by Target Retrieval Solution pH6.0 (DAKO #S1699)) and mouse fetal tissue was performed using Autostainer (Dako) and sections were counterstained with hematoxylin. Detection of HIF-2α by immunofluorescence was performed by incubation of embryo sections in ice cold acetone followed by 0.3% Triton-X in PBS. After washing in PBS, slides were blocked in DAKO serum-free ready-to-use block (DAKO, #X0909) for 1 hour before incubation with primary antibody (in DAKO antibody diluent with background reducing components (DAKO, #S3022)) overnight. Slides were washed in PBS and incubated with rabbit linker (DAKO, #K8019) followed by secondary antibody in 1% BSA/PBS. Detection of HNK1 and SOX9 by immunofluorescence was performed by blocking (10% goat serum and 0.3% Triton-X in TBST) of embryo sections followed by incubation with primary antibodies over night at +4°C. Slides were washed and incubated with secondary antibodies and DAPI for nuclear staining for 1 hour at RT before washing and mounting. Fluorescent images were acquired using an Olympus BX63 microscope, DP80 camera, and cellSens Dimension v 1.12 software (Olympus Cooperation). Detailed information on antibodies can be found in Supplemental Table S5.

564 *RNA extraction and quantitative real-time PCR*

565 Total RNA was extracted using the RNAqueous Micro Kit (Ambion, #AM1931). Wild type
566 whole embryos were carefully mechanically dissociated before lysis, pooling 2 to 4 embryos
567 for each developmental stage. cDNA synthesis using random primers and qRT-PCR was
568 performed as previously described (Mohlin et al., 2015). Relative mRNA levels were
569 normalized to expression of two (avian; *18S, 28S*) or three (human; *UBC*, *SDHA*, *YWHAZ*)
570 reference genes using the comparative Ct method (Vandesompele et al., 2002). Detailed
571 information of primer sequences can be found in Supplementary Table S6.

572

573 *Fractionation and western blot*

574 Cytoplasmic and nuclear extraction of proteins was performed using the NE-PER Nuclear and
575 Cytoplasmic Extraction Reagents (Thermo Scientific). Proteins were separated by SDS-PAGE
576 and transferred to HyBond-C-Extra nitrocellulose membranes. Detailed information on
577 antibodies can be found in Supplemental Table S5.

578

579 *Oxygen sensing*

580 Oxygen concentrations were measured through the trunk region of developing chick embryos
581 *ex ovo* using microsensors in a flow system of MQ water. Microprofiles were measured in 50
582 embryos in developmental stages HH10 to HH24. Embryos were removed from the egg using
583 filter paper as described in Mohlin and Kerosuo (Mohlin & Kerosuo, 2019), submerged in a
584 plate with constant flow of newly shaken MQ of room temperature, and immediately measured.
585 Oxygen microsensors were constructed and calibrated as described by Revsbech and Andersen
586 (Revsbech & Andersen, 1989), mounted on a micromanipulator. The microsensor was

manually probing the trunk region and data logged every second. Within the microprofile, ten consecutive data points of the lowest oxygen concentrations were averaged and set as representing the trunk neural tube. A two-point calibration was performed using the newly shaken MQ (100% oxygen saturation) and by adding sodium dithionite to non-flowing MQ in the plate after measurements (0% oxygen saturation). Salinity of the tissue was determined using a conductivity meter (WTW 3110) and room temperature noted. The tissue is considered a liquid, where full oxygen saturation at 5 ‰ salinity and 25°C corresponds to 250 µm/l, 160 mmHg or 21% atmospheric $O_2$. Data was averaged for each HH stage including one measurement of the previous and subsequent HH stages. Replicates vary from three to ten biologically independent data points. Data is presented as percent of maximum saturation in the solution of the specific temperature and salinity.

*Quantifications*

Embryonic development was quantified in two ways; by determining the HH stage of embryos *in ovo* using head and tail morphology or by counting the number of somites of dissected embryos *ex ovo*. The number of embryos (n) for each group is denoted in respective figure legend. The fraction of proliferating EdU+ cells was determined by quantifying the number of GFP+ proliferating cells as well as RFP+ construct targeted cells and divide the number of double positive cells with the number of RFP+ cells. Only neural crest cells were included (distinguished by the dotted line in figures).

*Statistical methods and data sets*

One-way ANOVA or two-sided student's unpaired *t* test was used for statistical analyses. Publicly available dataset Cancer Cell Line Encyclopedia (CCLE) (R2: microarray analysis and visualization platform (http://r2.amc.nl)) was used to analyze gene expression across cell lines

612 from different cancer types. For downstream analysis on the 97 DEGs where the software IPA
613 was used, the statistical tests considered were p-value calculations using right-tailed Fisher
614 Exact Test.

615

**Acknowledgments**

We would like to thank Erica Hutchins, Shashank Gandhi and Siv Beckman for skillful technical assistance and Anni Glud and Ronnie N. Glud for providing microsensor technique and expertise. This work was supported by the Swedish Cancer Society, the Swedish Childhood Cancer Fund, the Craaford Foundation, Jeansson Foundations, Ollie and Elof Ericsson's foundation, the Mary Bevé Foundation, Magnus Bergvall's foundation, the Thelma Zoéga foundation for medical research, Hans von Kantzow's foundation, the Royal Physiographic Society of Lund, the Gyllenstierna Krapperup's Foundation, and Gunnar Nilssons Cancerstiftelse (to SM), DE027568 and R01HL14058 (to MEB). We thank Center for Translational Genomics, Lund University and Clinical Genomics Lund, SciLifeLab for providing sequencing service. Support by NBIS (National Bioinformatics Infrastructure Sweden) is gratefully acknowledged.

**Author contributions**

SM, CUP, EF and EH performed experiments. SM, EH and MEB analyzed data. SM and JML analyzed RNA sequencing data. EM and ZK provided materials. SM and MEB supervised the study. SM wrote the original draft of the manuscript while all authors reviewed and edited the manuscript.

**Competing interests**

The authors declare no competing interests.

641 **References**

642 Acloque, H., Wilkinson, D. G., & Nieto, M. A. (2008). In situ hybridization analysis of chick
643 embryos in whole-mount and tissue sections. *Methods Cell Biol, 87*, 169-185.
644 doi:10.1016/S0091-679X(08)00209-4

645 Ayer-Le Lievre, C. S., & Le Douarin, N. M. (1982). The early development of cranial sensory
646 ganglia and the potentialities of their component cells studied in quail-chick chimeras.
647 *Dev Biol, 94*(2), 291-310. doi:10.1016/0012-1606(82)90349-9

648 Bishop, T., Gallagher, D., Pascual, A., Lygate, C. A., de Bono, J. P., Nicholls, L. G., . . .
649 Ratcliffe, P. J. (2008). Abnormal sympathoadrenal development and systemic
650 hypotension in PHD3-/- mice. *Mol Cell Biol, 28*(10), 3386-3400.
651 doi:10.1128/MCB.02041-07

652 Bittencourt, D. A., da Costa, M. C., Calloni, G. W., Alvarez-Silva, M., & Trentin, A. G. (2013).
653 Fibroblast growth factor 2 promotes the self-renewal of bipotent glial smooth muscle
654 neural crest progenitors. *Stem Cells Dev, 22*(8), 1241-1251. doi:10.1089/scd.2012.0585

655 Braekeveldt, N., Wigerup, C., Gisselsson, D., Mohlin, S., Merselius, M., Beckman, S., . . .
656 Bexell, D. (2015). Neuroblastoma patient-derived orthotopic xenografts retain
657 metastatic patterns and geno- and phenotypes of patient tumours. *Int J Cancer, 136*(5),
658 E252-261. doi:10.1002/ijc.29217

659 Bronner-Fraser, M., & Fraser, S. E. (1988). Cell lineage analysis reveals multipotency of some
660 avian neural crest cells. *Nature, 335*(6186), 161-164. doi:10.1038/335161a0

661 Covello, K. L., Kehler, J., Yu, H., Gordan, J. D., Arsham, A. M., Hu, C. J., . . . Keith, B. (2006).
662 HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic
663 development, and tumor growth. *Genes Dev, 20*(5), 557-570. doi:10.1101/gad.1399906

664 De Preter, K., Vandesompele, J., Heimann, P., Yigit, N., Beckman, S., Schramm, A., . . .
665 Speleman, F. (2006). Human fetal neuroblast and neuroblastoma transcriptome analysis

confirms neuroblast origin and highlights neuroblastoma candidate genes. *Genome Biol, 7*(9), R84. doi:10.1186/gb-2006-7-9-r84

Edgar, R., Domrachev, M., & Lash, A. E. (2002). Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. *Nucleic Acids Res, 30*(1), 207-210. doi:10.1093/nar/30.1.207

Frith, T. J., Granata, I., Wind, M., Stout, E., Thompson, O., Neumann, K., . . . Tsakiridis, A. (2018). Human axial progenitors generate trunk neural crest cells in vitro. *Elife, 7*. doi:10.7554/eLife.35786

Furlan, A., Dyachuk, V., Kastriti, M. E., Calvo-Enrique, L., Abdo, H., Hadjab, S., . . . Adameyko, I. (2017). Multipotent peripheral glial cells generate neuroendocrine cells of the adrenal medulla. *Science, 357*(6346). doi:10.1126/science.aal3753

Gandhi, S., Haeussler, M., Razy-Krajka, F., Christiaen, L., & Stolfi, A. (2017). Evaluation and rational design of guide RNAs for efficient CRISPR/Cas9-mediated mutagenesis in Ciona. *Dev Biol, 425*(1), 8-20. doi:10.1016/j.ydbio.2017.03.003

Hamburger, V., & Hamilton, H. L. (1951). A series of normal stages in the development of the chick embryo. *J Morphol, 88*(1), 49-92.

Hoehner, J. C., Gestblom, C., Hedborg, F., Sandstedt, B., Olsen, L., & Pahlman, S. (1996). A developmental model of neuroblastoma: differentiating stroma-poor tumors' progress along an extra-adrenal chromaffin lineage. *Lab Invest, 75*(5), 659-675.

Holmquist-Mengelbier, L., Fredlund, E., Lofstedt, T., Noguera, R., Navarro, S., Nilsson, H., . . . Pahlman, S. (2006). Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. *Cancer Cell, 10*(5), 413-423. doi:10.1016/j.ccr.2006.08.026

Kastriti, M. E., Kameneva, P., Kamenev, D., Dyachuk, V., Furlan, A., Hampl, M., . . . Adameyko, I. (2019). Schwann Cell Precursors Generate the Majority of Chromaffin

691 Cells in Zuckerkandl Organ and Some Sympathetic Neurons in Paraganglia. *Front Mol*
692 *Neurosci, 12*, 6. doi:10.3389/fnmol.2019.00006
693 Kerosuo, L., Nie, S., Bajpai, R., & Bronner, M. E. (2015). Crestospheres: Long-Term
694 Maintenance of Multipotent, Premigratory Neural Crest Stem Cells. *Stem Cell Reports,*
695 *5*(4), 499-507. doi:10.1016/j.stemcr.2015.08.017
696 Khudyakov, J., & Bronner-Fraser, M. (2009). Comprehensive spatiotemporal analysis of early
697 chick neural crest network genes. *Dev Dyn, 238*(3), 716-723. doi:10.1002/dvdy.21881
698 Koh, M. Y., Lemos, R., Jr., Liu, X., & Powis, G. (2011). The hypoxia-associated factor switches
699 cells from HIF-1alpha- to HIF-2alpha-dependent signaling promoting stem cell
700 characteristics, aggressive tumor growth and invasion. *Cancer Res, 71*(11), 4015-4027.
701 doi:10.1158/0008-5472.CAN-10-4142
702 Kramer, A., Green, J., Pollard, J., Jr., & Tugendreich, S. (2014). Causal analysis approaches in
703 Ingenuity Pathway Analysis. *Bioinformatics, 30*(4), 523-530.
704 doi:10.1093/bioinformatics/btt703
705 Love, M. I., Huber, W., & Anders, S. (2014). Moderated estimation of fold change and
706 dispersion for RNA-seq data with DESeq2. *Genome Biol, 15*(12), 550.
707 doi:10.1186/s13059-014-0550-8
708 Maris, J. M. (2010). Recent advances in neuroblastoma. *N Engl J Med, 362*(23), 2202-2211.
709 doi:10.1056/NEJMra0804577
710 Mohlin, S., Hamidian, A., & Pahlman, S. (2013). HIF2A and IGF2 expression correlates in
711 human neuroblastoma cells and normal immature sympathetic neuroblasts. *Neoplasia,*
712 *15*(3), 328-334. doi:10.1593/neo.121706
713 Mohlin, S., Hamidian, A., von Stedingk, K., Bridges, E., Wigerup, C., Bexell, D., & Pahlman,
714 S. (2015). PI3K-mTORC2 but not PI3K-mTORC1 regulates transcription of

715 HIF2A/EPAS1 and vascularization in neuroblastoma. *Cancer Res, 75*(21), 4617-4628.
716 doi:10.1158/0008-5472.CAN-15-0708
717 Mohlin, S., Hansson, K., Radke, K., Martinez, S., Blanco-Apiricio, C., Garcia-Ruiz, C., . . .
718 Bexell, D. (2019). Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-
719 302 in neuroblastoma. *EMBO Mol Med, 11*(8), e10058.
720 doi:10.15252/emmm.201810058
721 Mohlin, S., & Kerosuo, L. (2019). In Vitro Maintenance of Multipotent Neural Crest Stem Cells
722 as Crestospheres. *Methods Mol Biol, 2002*, 1-11. doi:10.1007/7651_2018_180
723 Mohlin, S., Kunttas, E., Persson, C. U., Abdel-Haq, R., Castillo, A., Murko, C., . . . Kerosuo,
724 L. (2019). Maintaining multipotent trunk neural crest stem cells as self-renewing
725 crestospheres. *Dev Biol, 447*(2), 137-146. doi:10.1016/j.ydbio.2019.01.010
726 Murko, C., Vieceli, F. M., & Bronner, M. (2018). Transcriptome dataset of trunk neural crest
727 cells migrating along the ventral pathway of chick embryos. *Data Brief, 21*, 2547-2553.
728 doi:10.1016/j.dib.2018.11.109
729 Persson, C. U., von Stedingk, K., Bexell, D., Merselius, M., Braekeveldt, N., Gisselsson, D., .
730 . . Wigerup, C. (2017). Neuroblastoma patient-derived xenograft cells cultured in stem-
731 cell promoting medium retain tumorigenic and metastatic capacities but differentiate in
732 serum. *Sci Rep, 7*(1), 10274. doi:10.1038/s41598-017-09662-8
733 Petrella, B. L., Lohi, J., & Brinckerhoff, C. E. (2005). Identification of membrane type-1 matrix
734 metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau
735 renal cell carcinoma. *Oncogene, 24*(6), 1043-1052. doi:10.1038/sj.onc.1208305
736 Pietras, A., Gisselsson, D., Ora, I., Noguera, R., Beckman, S., Navarro, S., & Pahlman, S.
737 (2008). High levels of HIF-2alpha highlight an immature neural crest-like
738 neuroblastoma cell cohort located in a perivascular niche. *J Pathol, 214*(4), 482-488.
739 doi:10.1002/path.2304

740 Pietras, A., Hansford, L. M., Johnsson, A. S., Bridges, E., Sjolund, J., Gisselsson, D., . . .
741 Pahlman, S. (2009). HIF-2alpha maintains an undifferentiated state in neural crest-like
742 human neuroblastoma tumor-initiating cells. *Proc Natl Acad Sci U S A, 106*(39), 16805-
743 16810. doi:10.1073/pnas.0904606106
744 Revsbech, P., & Andersen, G. (1989). Diurnal variation in peak expiratory flow rate among
745 grain elevator workers. *Br J Ind Med, 46*(8), 566-569. doi:10.1136/oem.46.8.566
746 Soldatov, R., Kaucka, M., Kastriti, M. E., Petersen, J., Chontorotzea, T., Englmaier, L., . . .
747 Adameyko, I. (2019). Spatiotemporal structure of cell fate decisions in murine neural
748 crest. *Science, 364*(6444). doi:10.1126/science.aas9536
749 Thomas, P. D., Campbell, M. J., Kejariwal, A., Mi, H., Karlak, B., Daverman, R., . . .
750 Narechania, A. (2003). PANTHER: a library of protein families and subfamilies
751 indexed by function. *Genome Res, 13*(9), 2129-2141. doi:10.1101/gr.772403
752 Tian, H., Hammer, R. E., Matsumoto, A. M., Russell, D. W., & McKnight, S. L. (1998). The
753 hypoxia-responsive transcription factor EPAS1 is essential for catecholamine
754 homeostasis and protection against heart failure during embryonic development. *Genes*
755 *Dev, 12*(21), 3320-3324. doi:10.1101/gad.12.21.3320
756 Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A., & Speleman,
757 F. (2002). Accurate normalization of real-time quantitative RT-PCR data by geometric
758 averaging of multiple internal control genes. *Genome Biol, 3*(7), RESEARCH0034.
759 doi:10.1186/gb-2002-3-7-research0034
760 Vega-Lopez, G. A., Cerrizuela, S., Tribulo, C., & Aybar, M. J. (2018). Neurocristopathies: New
761 insights 150 years after the neural crest discovery. *Dev Biol, 444 Suppl 1*, S110-S143.
762 doi:10.1016/j.ydbio.2018.05.013
763 Warren, M., Puskarczyk, K., & Chapman, S. C. (2009). Chick embryo proliferation studies
764 using EdU labeling. *Dev Dyn, 238*(4), 944-949. doi:10.1002/dvdy.21895

765

766

767

## Figure Legends

**Fig. 1.** *HIF-2α is expressed in trunk neural crest cells.* **A.** Western blot of fractionated wild type HH18 chick embryos show HIF-2α protein expression in cytoplasmic and nuclear compartments (cf. panel **C-F**). Blot shown is a representative of multiple experiments. SDHA was used as loading control. **B.** Relative mRNA expression over developmental time (HH4 to HH27) in whole wild type chick embryos. *EPAS1* expression was measured using qRT-PCR and is presented as mean of n=2 biological replicates. Error bars represent SEM. **C-D.** Immunostaining of HIF-2α in sections from trunk axial level of wild type chick embryos at premigratory HH11 **(C)** and HH13 **(D)** stages. Arrows denote scattered HIF-2α positive cells within the dorsal neural tube. **E.** Immunostaining of HIF-2α in sections from trunk axial level of wild type chick embryos at migratory HH18 stage. Arrows denote ventrally migrating HIF-2α positive cells. **F.** A different section from embryo in **(E)** with magnification (dashed square). **G.** Oxygen saturation (%) in the trunk of chick embryos during development measured *ex ovo* using microsensor technique. Error bars represent SEM.

**Fig. 2.** *HIF-2α is expressed in human and mouse trunk neural crest cells.* **A.** Immunohistochemical staining of HIF-2α in sections from a mouse embryo at embryonic day E12.5. **B.** Immunohistochemical staining of TH in adjacent section to **(A)** to locate sympathetic ganglia. **A-B.** Asterisk in left panels locate HIF-2α$^{+}$ and TH$^{+}$ cells within sympathetic ganglia. Asterisk also indicate magnified area in middle panels and dashed square indicates magnification area in right panels. **C.** Immunohistochemical staining of HIF-2α in sections from trunk axial level of a human embryo at embryonic week ew5. Arrowhead represents magnification in upper right panel. Asterisk represents magnification in lower left panel and dashed square represent magnified area in lower right panel. **(A-C)** Sections are counterstained

793 with hematoxylin to visualize tissue structure and nuclei. **D-E.** Immunostaining of HIF-2α in
794 sections from trunk axial level of human embryos at embryonic week ew5 **(D)** and embryonic
795 week ew6 **(E)**. Arrow denotes HIF-2α positive migrating cells. ew, embryonic week; NC,
796 neural crest. DAPI was used to stain nuclei.
797
798 **Fig. 3.** *Knockdown of HIF-2α delays embryogenesis.* **A.** Hamburger Hamilton (HH) staging of
799 embryos 36 hours post-electroporation with a non-targeting (CTRL) gRNA compared to three
800 different gRNAs targeting *EPAS1* (EPAS1.1, EPAS1.2, EPAS1.3) by head- and tail
801 morphology. Number of embryos analyzed were n=14 (CTRL), n=10 (EPAS1.1), n=14
802 (EPAS1.2) and n=14 (EPAS1.3). Statistical significance was determined by one-way ANOVA
803 comparing non-targeting CTRL with each individual *EPAS1* gRNA. **B.** Hamburger Hamilton
804 (HH) staging of embryos 44 hours post-electroporation with 5'-mispair or *EPAS1* targeting
805 morpholinos by head- and tail morphology. Number of embryos analyzed were n=20 (5'-
806 mispair), n=16 (EPAS1). Statistical significance was determined by one-way ANOVA. **C.**
807 Determination of embryonic age by number of somites 36 hours post-electroporation. Number
808 of embryos analyzed were n=8 (CTRL), n=13 (EPAS1.1) and n=14 (EPAS1.3). Statistical
809 significance was determined by one-way ANOVA comparing non-targeting CTRL with each
810 individual *EPAS1* gRNA. **D.** Determination of embryonic age by number of somites 44 hours
811 post-electroporation. Number of embryos analyzed were n=17 (5'-mispair), n=15 (EPAS1).
812 Statistical significance was determined by one-way ANOVA. **E-F.** Relative mRNA expression
813 of /trunk/ neural crest **(E)** and cranial neural crest **(F)** associated genes in trunk neural crest
814 cells derived from embryos electroporated with 5'-mispair or *EPAS1* morpholinos, measured
815 by qRT-PCR 24 hours post-electroporation. **G-H.** Relative mRNA expression of trunk neural
816 crest **(G)** and cranial neural crest **(H)** associated genes in trunk neural crest cells derived from
817 embryos electroporated with non-targeting CTRL or three *EPAS1* gRNAs, measured by qRT-

PCR 24 hours post-electroporation. **E-H.** Data presented as mean of n=2 biologically independent repeats, error bars denote SEM. Statistical significance was determined by two-sided student's t-test (**E-H**), comparing non-targeting CTRL with each individual *EPAS1* gRNA in **G-H**.

**Fig. 4.** *Knockdown of HIF-2α affects migration of trunk neural crest cells.* **A-D.** Immunostaining of HNK1 (red) marking migrating crest cells in one-sided electroporated embryos (right side). Electroporated cells (non-targeting CTRL gRNA **(A)**, gRNA #2 targeting *EPAS1* (EPAS1.2; **B**), 5'-mispair morpholino **(C)** or *EPAS1* morpholino **(D)**) are seen in green. DAPI was used to counterstain nuclei. Embryo sections from trunk axial level are from 48 hours (**A-B**) or 44 hours (**C-D**) post-electroporation.

**Fig. 5**. *Controlled expression of HIF-2α is required to maintain embryonic homeostasis.* **A.** Hamburger Hamilton (HH) staging of embryos 24 hours post-electroporation with a control (pCI-CTRL) or *EPAS1* overexpression construct (pCI-EPAS1), determined by head- and tail morphology. Number of embryos analyzed were n=16 (CTRL), n=20 (EPAS1). Statistical significance was determined by one-way ANOVA. **B.** Immunostaining of HNK1 (green) marking migrating crest cells in one-sided electroporated embryos (right side). Electroporated cells (CTRL or EPAS1) are seen in red. DAPI was used to counterstain nuclei. Embryo sections from trunk axial level are taken 48 hours post- electroporation. **C.** Relative mRNA expression of /trunk/ neural crest and cranial neural crest genes in trunk neural crest cells derived from embryos electroporated with CTRL or EPAS1 vectors, measured by qRT-PCR 24 hours post-electroporation. Data presented as mean of n=2 biologically independent repeats, error bars denote SEM. Statistical significance was determined by two-sided student's t-test.

**Fig. 6**. *Knockdown of HIF-2α affects proliferation and stemness of trunk neural crest cells*. **A-D.** Embryo sections from trunk axial level after real-time EdU labeling. Proliferating $EdU^+$ cells are seen in green and electroporated cells (5'-mispair and *EPAS1* morpholinos (**A**); pCI-CTRL and pCI-EPAS1 (**C**)) are seen in red. DAPI was used to counterstain nuclei. Quantification of proliferating cells was performed by manual counting of $RFP^+$ only as well as double positive cells. Only construct targeted trunk neural crest cells (above dotted line) were included. Number of cells analyzed were n=82 (5'-mispair morpholino) and n=303 (EPAS1 morpholino) **(B)**; n=211 (pCI-CTRL) and n=139 (pCI-EPAS1) **(D)**. **E.** Relative mRNA expression of *EPAS1* in wild type HH10 embryos (blue bar) and crestosphere cells established from the cranial axial level (green bar) or trunk axial level (yellow bar) measured by qRT-PCR. Expression is presented as mean of n=4 (cranial) or n=3 (trunk) biological replicates and error bars represent SEM. Expression difference between cranial and trunk crestospheres, p=0.056, as determined by two-sided student's t test. Expression in wild type HH10 embryos is presented as mean of n=3 technical replicates. **F.** *In situ* detection of *EPAS1* mRNA in trunk derived crestospheres. **G.** Primary sphere assay, i.e. quantification of self-renewal from crestospheres established from dissociated trunk neural tubes of HH13+/14- embryos previously electroporated *in ovo* at $HH10^+$/HH11 with non-targeting gRNA (CTRL) or gRNA targeting *EPAS1* (EPAS1.1). One cell/well (n=10 wells per group) were seeded at T= 0 days. Number of spheres were manually counted in each well after T= 1 week. Statistical significance was determined by one-way ANOVA. **H.** Quantification of self-renewal (as described in **G.**) and sphere size from crestospheres established from dissociated trunk neural tubes of HH13+/14- embryos electroporated with non-targeting gRNA (CTRL) or gRNA targeting *EPAS1* (EPAS1.2). Sphere size by manual measurements converted to factual unit (μm). Statistical significance was determined by one-way ANOVA.

**Fig. 7.** *Gene set enrichment analysis identifies HIF-2α downstream affected processes*. **A-B.** Hierarchical clustering of significantly Differentially Expressed Genes (DEGs;cut-off p<0.005) identified from RNA sequencing comparing 5'-mispair and *EPAS1* morpholino samples. **C.** List of the top ten upregulated and top ten downregulated genes from the RNA sequencing data. **D.** Hypothesis-free/exploratory analysis of the 97 DEGs using IPA (Fishers Exact Test for the range of p-value calculation) revealed a series of top five hits (p<0.05) in the respective categories "Disease and Disorders", "Molecular and Cellular Functions" and "Physiological System Development and Function" downstream processes**. E.** Deeper analysis of processes identified in **(D)**. **F.** Selected list of enriched cellular processes from Panther analyses. Complete list can be found in **Supplemental Table S2**. **G.** Deeper analysis of potential upstream regulators of the "arrest in embryo growth" process identified in **E**. The shape of molecules and their meaning, i.e. correspondence to protein family etc., is found here: http://qiagen.force.com/KnowledgeBase/KnowledgeIPAPage?id=kA41i000000L5rTCAS. As an example, the diamond shaped molecules correspond to enzymes, oval standing shapes should be read as transmembrane receptors and lying oval shapes are transcription regulators. Green nodes indicate down-regulated molecules. The intensity of the color reveals the strength of the expression i.e. the stronger the color the more significant.

**Fig. 8.** *Trunk neural crest associated genes are enriched in neuroblastoma.* **A.** Trunk neural crest (*RASL11B*, *TAGLN3* and *NRCAM*) gene expression in cancer types of different tissue origins. Data from the Cancer Cell Line Encyclopedia (CCLE) dataset, tissue origin with samples n>3 were chosen for further analysis. Number in brackets represents the number of cell lines from each tissue origin. Arrows highlight neuroblastoma. **B-C.** Relative mRNA expression of neural crest (*TFAP2B*, **(B)**) and trunk neural crest (*RASL11B*, *FMN2*, *TAGLN3*

and *NRCAM* **(C)**) genes measured by qRT-PCR. Expression in LU-NB-3 neuroblastoma (NB) patient-derived xenograft cells were compared to liver cancer (Li) Hep3B and clear cell renal cell carcinoma (ccRCC) RCC-4 and 786-0 cell lines. Data are presented as mean of n=3 biologically independent replicates and error bars represent SEM. Statistical significance comparing Hep3B, RCC-4 or 786-0 individually to LU-NB-3 was tested using two-sided students *t test*. **D.** Schematic summary of developmental effects following dysregulated HIF-2α expression levels in trunk neural crest cells.

**Table 1.** Selected genes identified as potential upstream regulators of arrested embryo growth. Genes associated with stem cells **(A)**, BMP signaling **(B)** and EMT **(C)** were particularly enriched.

**Supplemental Fig. S1.** *Specificity control of antibodies.* **A.** Sections of HH13 wild type embryo immunostained with DAPI for visualization of nuclei and secondary antibody only (donkey anti-rabbit Alexa Fluor-546). **B.** Immunohistochemical staining for HIF-2α in sections of SK-N-BE(2)c neuroblastoma cells cultured at normoxia (21% $O_2$) or hypoxia (1% $O_2$). HIF-2α positive cells are as expected detected at hypoxia and demonstrate nuclear and cytoplasmic expression.

**Supplemental Fig. S2.** *Electroporation of knockdown constructs is efficient.* **A-B.** Relative mRNA expression of *EGFP* in embryos electroporated with morpholinos (cf. **Figure 3E-F**) **(A)** or CRISPR constructs (cf. **Figure 3G-H**) **(B)** measured by qRT-PCR. Expression of *EGFP* in electroporated embryos was compared to expression in wild type HH18 embryos. **C-D.** Neural crest **(C)** and early or late/migratory neural crest **(D)** genes in trunk neural crest cells derived from embryos electroporated with non-targeting (CTRL) or three *EPAS1* gRNAs,

measured by qRT-PCR 24 hours post-electroporation. Data are presented as mean of n=2 biologically independent replicates and error bars represent SEM. Statistical significance comparing each individual *EPAS1* targeting gRNA to control (CTRL), respectively, was determined by two-sided student's t-test.

**Supplemental Fig. S3.** *SOX9 expression is not affected by HIF-2α knockdown.* **A-C.** Immunostaining of SOX9 (red) in one-sided electroporated embryos (right side). Electroporated cells (non-targeting gRNA (CTRL), **(A)**) or gRNA #1 (EPAS1.1, **(B)**) and #3 (EPAS1.3, **(C)**) targeting EPAS1) are seen in green. DAPI was used to counterstain nuclei. Embryo sections from trunk axial level are from 48 hours post-electroporation.

**Supplemental Fig. S4.** *Electroporation of overexpression constructs is efficient* **A.** Relative mRNA expression of neural crest associated genes in trunk neural crest cells derived from embryos electroporated with pCI-CTRL or pCI-EPAS1 vectors, measured by qRT-PCR 24 hours post-electroporation. Data presented as mean of n=2 biologically independent repeats, error bars denote SEM. Statistical significance was determined by two-sided student's t-test. **B.** Relative mRNA expression of *EPAS1* in embryos electroporated with pCI-CTRL or pCI-EPAS1 for overexpression of HIF-2α (cf. **Figure 5**). Data are presented as mean of n=2 biologically independent replicates and error bars represent SEM.

**Supplemental Fig. S5.** *Gene set enrichment analysis identifies key molecules.* **A.** Top network composed by analyzing significantly Differentially Expressed Genes from RNA sequencing data. **B.** Deeper analysis of overlap of genes involved in downstream process "migration of tumor cells" and genes from RNA sequencing data. **A-B.** The shape of molecules and their meaning, i.e. correspondence to protein family etc., is found here:

http://qiagen.force.com/KnowledgeBase/KnowledgeIPAPage?id=kA41i000000L5rTCAS. As an example, the diamond shaped molecules correspond to enzymes, oval standing shapes should be read as transmembrane receptors and lying oval shapes are transcription regulators. Green nodes indicate down-regulated molecules. The intensity of the color reveals the strength of the expression i.e. the stronger the color the more significant. The dashed lines indicate an indirect interaction between molecules in the network whereas solid lines are direct interactions. The solid arrow explains the direction of the indicated interaction. A line, solid or dashed, without an arrowhead indicate an RNA-RNA interaction. **C.** Schematic of the gene regulatory network including *EPAS1* and downstream *CDX2* and *HNF1B* coupled to arrested embryo growth.

**Supplemental Fig. S6.** *Trunk neural crest associated genes are enriched in neuroblastoma.* **A-D.** Neural crest (*TFAP2B* **(A)**), trunk neural crest (*AGPAT4*, *FMN2*, *HES6*, *HES5* and *HOXC9* **(B-C)**) and cranial neural crest (*HOXA2* **(D)**) gene expression in cancer types of different tissue origins. Data from the Cancer Cell Line Encyclopedia (CCLE) dataset, tissue origin with samples n>3 were chosen for further analysis. Arrows highlight neuroblastoma. **E.** Relative mRNA expression of neural crest (*SOX10*) and trunk neural crest (*HES6, AGPAT4, HES5*) genes measured by qRT-PCR. Expression in LU-NB-3 neuroblastoma (NB) patient-derived xenograft cells were compared to liver cancer (Li) Hep3B and clear cell renal cell carcinoma (ccRCC) RCC-4 and 786-0 cell lines. Data are presented as mean of n=3 biologically independent replicates and error bars represent SEM. Statistical significance comparing Hep3B, RCC-4 or 786-0 to LU-NB-3, respectively, was tested using two-sided students *t test*.

**Supplemental Table S1.** Full list of the 97 significantly (p<0.005) DEGs between 5'-mispair and *EPAS1* morpholino samples identified by RNA sequencing. Relates to **Fig. 7A-B**.

968

969 **Supplemental Table S2**. Full list of processes identified by PANTHER analysis. Relates to

970 **Fig. 7F**.

971

972 **Supplemental Table S3.** Full list of genes identified as potential upstream regulators of "arrest

973 in embryo growth". Relates to **Table 1**.

974

975 **Supplemental Table S4.** Full list of genes identified as potential upstream regulators of HIF-

976 2α from RNA sequencing data. Target molecules are among the 97 significantly ($p<0.005$)

977 DEGs between 5'-mispair and *EPAS1* morpholino samples identified by RNA sequencing.

978

979 **Supplemental Table S5.** Details of antibodies.

980

981 **Supplemental Table S6.** List of primer sequences used for qRT-PCR analyses.

Figure 1





Figure 3



Figure 4



Figure 5



Figure 6



Figure 7

A




B




C

Top 10 genes up and down

| Gene_name | log2FoldChange |
|---|---|
| DLX3 | -5,237610938 |
| TSPAN8 | -3,77045907 |
| TFAP2E | -3,18357506 |
| DCDC2 | -3,035920312 |
| SLC12A3 | -2,700635689 |
| OVAL | -2,685319715 |
| CDX2 | -2,4394251 |
| HNF1B | -2,281631746 |
| ASL1 | -2,269756179 |
| CD200L | -2,132229985 |
| CHST8 | 2,680876707 |
| GAL | 2,641577626 |
| SCARB1 | 2,040797789 |
| POSTN | 1,786031417 |
| TNNC1 | 1,720938851 |
| FSTL4 | 1,704294412 |
| KRT15 | 1,634804647 |
| LY86 | 1,615548567 |
| ZNF385D | 1,483429288 |
| FBXO48 | 1,321581752 |

D

| Diseases and Disorders | p-value | # Molecules |
|---|---|---|
| Cancer | 7.47e-03 - 1.9e-06 | 76 |
| Organismal Injury and Abnormalities | 7.47e-03 - 1.9e-06 | 78 |
| Reproductive System Disease | 7.47e-03 - 1.9e-06 | 57 |
| Tumor Morphology | 7.47e-03 - 2.79e-06 | 8 |
| Endocrine System Disorders | 7.47e-03 - 5.32e-06 | 27 |

| Molecular and Cellular Functions | p-value | # Molecules |
|---|---|---|
| Cellular Assembly and Organization | 7.47e-03 - 4.86e-06 | 24 |
| Cellular Movement | 7.47e-03 - 8.63e-05 | 29 |
| Cellular Development | 7.47e-03 - 1.9e-04 | 23 |
| Cell Cycle | 7.47e-03 - 1.37e-04 | 12 |
| Cell Morphology | 7.47e-03 - 1.37e-04 | 18 |

| Physiological System Development and Function | p-value | # Molecules |
|---|---|---|
| Tissue Morphology | 7.47e-03 - 2.79e-06 | 24 |
| Embryonic Development | 7.47e-03 - 2.3e-05 | 29 |
| Organismal Development | 7.47e-03 - 2.3e-05 | 23 |
| Tissue Development | 7.47e-03 - 1.09e-04 | 12 |

E

Invasion of tumor cells
Size and volume of tumor

Migration of tumor cells
Invasion
Epithelial-to-Mesenchymal Transition

Arrest in embryo growth
Development of body trunk

F

| | | Fold Enrichment | p value |
|---|---|---|---|
| Development | regulation of multicellular organismal development (GO:2000026) | 3.01 | 1.48E-05 |
| | regulation of developmental process (GO:0050793) | 2.57 | 4.79E-05 |
| | anatomical structure development (GO:0048856) | 2.04 | 2.70E-05 |
| | multicellular organism development (GO:0007275) | 2.03 | 8.99E-05 |
| | developmental process (GO:0032502) | 1.98 | 3.99E-05 |
| | regulation of cell differentiation (GO:0045595) | 3.43 | 2.27E-06 |
| Cellular localization | positive regulation of cellular protein localization (GO:1903829) | 7.55 | 4.91E-05 |
| | regulation of cellular protein localization (GO:1903827) | 7.09 | 5.64E-07 |
| | regulation of cellular localization (GO:0060341) | 4.52 | 1.54E-05 |
| | regulation of protein localization (GO:0032880) | 3.98 | 1.11E-04 |
| | maintenance of mitochondrion location (GO:0051659) | > 100 | 1.44E-04 |
| Migration | cell migration (GO:0016477) | 4.37 | 2.16E-05 |
| | cell motility (GO:0048870) | 3.94 | 5.84E-05 |
| Signaling | positive regulation of phosphatidylinositol 3-kinase signaling (GO:0014068) | 17.17 | 1.16E-04 |
| | ephrin receptor signaling pathway (GO:0048013) | 26.03 | 2.58E-05 |

G




Upstream regulators of 'Arrest in embryo growth'

* Identified as downstream of EPAS1



A.

HIF-2α staining control




B.

SK-N-BE(2)c



Supplementary Figure S2



Supplementary Figure S3

A.




Control Electroporated

B.




Control Electroporated

C.




Control Electroporated

Supplementary Figure S4

A.




B.



Supplementary Figure S5

A.




B.




C.



Supplementary Figure S6

A. Neural crest




B. Trunk neural crest







C. Trunk neural crest










D. Cranial neural crest




E.



| Gene_stable_ID | Gene_name | log2FoldChange | p value |
|---|---|---|---|
| ENSGALG00000035219 | ALB | -1.117182632 | 0.004326406 |
| ENSGALG00000007599 | AMER1 | -0.405238741 | 0.000373362 |
| ENSGALG00000002723 | ANKS1A | -0.620471912 | 0.002221987 |
| ENSGALG00000020876 | AOX2 | -1.096918485 | 0.00085007 |
| ENSGALG00000000220 | APC | -0.47416616 | 0.000273889 |
| ENSGALG00000026364 | ASAH1 | 0.421872055 | 0.002627088 |
| ENSGALG00000002558 | ASL1 | -2.269756179 | 0.000254935 |
| ENSGALG00000014234 | ATXN10 | 0.477982264 | 0.001858816 |
| ENSGALG00000009642 | AVEN | 0.319184758 | 0.002524998 |
| ENSGALG00000039595 | BTBD11 | 1.074785502 | 0.000312368 |
| ENSGALG00000040463 | CABP7 | -1.850580177 | 0.003025143 |
| ENSGALG00000012095 | CCDC198 | -1.657954928 | 0.00269933 |
| ENSGALG00000006787 | CCDC71 | -0.470629203 | 0.002673943 |
| ENSGALG00000015395 | CD200L | -2.132229985 | 0.000154209 |
| ENSGALG00000000608 | CDH1 | -1.307331812 | 0.000773978 |
| ENSGALG00000034983 | CDX2 | -2.4394251 | 8.25E-05 |
| ENSGALG00000004687 | CENPP | 0.424109009 | 0.000169658 |
| ENSGALG00000037504 | CFAP36 | 0.393170817 | 0.00331114 |
| ENSGALG00000004903 | CHST8 | 2.680876707 | 0.004291268 |
| ENSGALG00000026862 | CLDN1 | -1.995178284 | 0.00010847 |
| ENSGALG00000007025 | CPNE8 | 1.148105385 | 0.004533116 |
| ENSGALG00000001169 | CRB2 | -0.810451518 | 0.001196479 |
| ENSGALG00000005657 | CRHR2 | -0.937081004 | 0.004656735 |
| ENSGALG00000042454 | DCDC2 | -3.035920312 | 0.003127781 |
| ENSGALG00000011274 | DCN | 0.981364002 | 0.002209936 |
| ENSGALG00000014700 | DHX29 | -0.444692933 | 0.003215344 |
| ENSGALG00000032937 | DLGAP2 | 1.296643213 | 0.003793901 |
| ENSGALG00000040529 | DLX3 | -5.237610938 | 0.001107996 |
| ENSGALG00000012156 | DPP10 | 1.123811132 | 0.001713737 |
| ENSGALG00000015403 | EPHA3 | 0.860641014 | 0.001951451 |
| ENSGALG00000004741 | EPHB2 | -0.418815561 | 0.001893072 |
| ENSGALG00000003126 | ERBB4 | -1.15424847 | 0.001506512 |
| ENSGALG00000031076 | ESRP1 | -1.882592181 | 0.001558762 |
| ENSGALG00000008332 | F2 | -1.908762077 | 0.001551013 |
| ENSGALG00000041153 | FAM109A | -1.215286589 | 0.004594595 |
| ENSGALG00000013503 | FAM149A | 0.797519339 | 0.004470883 |
| ENSGALG00000011099 | FAP | 1.014306518 | 0.00201386 |
| ENSGALG00000008753 | FBXO48 | 1.321581752 | 0.002069094 |
| ENSGALG00000010316 | FRAS1 | -0.558639554 | 0.001060929 |
| ENSGALG00000031487 | FSTL4 | 1.704294412 | 0.004365436 |
| ENSGALG00000007047 | GAL | 2.641577626 | 0.001941927 |
| ENSGALG00000028191 | GLCE | -0.598344895 | 0.000897534 |
| ENSGALG00000010350 | GPATCH2L | -0.487810446 | 7.98E-06 |
| ENSGALG00000041556 | GPATCH8 | -0.317242944 | 0.003590909 |
| ENSGALG00000037687 | GRHL2 | -1.807620277 | 0.003321608 |
| ENSGALG00000016124 | HADH | 0.25603248 | 0.003556043 |
| ENSGALG00000005504 | HNF1B | -2.281631746 | 0.00080264 |
| ENSGALG00000012009 | JKAMP | 0.382527526 | 0.003435274 |
| ENSGALG00000019718 | KRT15 | 1.634804647 | 0.000760169 |
| ENSGALG00000030710 | L3MBTL1 | -0.530953634 | 0.001495242 |
| ENSGALG00000036022 | LIN28A | -1.38546498 | 0.000196313 |
| ENSGALG00000012801 | LY86 | 1.615548567 | 0.003593197 |
| ENSGALG00000002379 | MRPS17 | 0.239466428 | 0.001783389 |
| ENSGALG00000007661 | MYCBPAP | -0.506429259 | 0.004333666 |
| ENSGALG00000031450 | MYO7A | -0.679727815 | 0.003592535 |
| ENSGALG00000002131 | NPRL2 | -0.499654709 | 0.003409913 |
| ENSGALG00000004245 | NUDT1 | 0.510897854 | 0.00012546 |
| ENSGALG00000013348 | OTUD7B | -0.376188595 | 0.001170227 |
| ENSGALG00000012869 | OVAL | -2.685319715 | 0.002991518 |
| ENSGALG00000042645 | PARD3B | -0.501189766 | 1.96E-06 |
| ENSGALG00000009378 | PDGFC | 0.796369213 | 0.001886551 |
| ENSGALG00000002963 | PID1 | 1.07251355 | 0.003711941 |
| ENSGALG00000001264 | PLXNA2 | -0.787868279 | 0.002137423 |
| ENSGALG00000006409 | PODXL | -0.886446619 | 0.004450686 |
| ENSGALG00000026210 | POMK | 0.337221928 | 0.003042971 |
| ENSGALG00000017046 | POSTN | 1.786031417 | 0.004588475 |
| ENSGALG00000016702 | PPP2R3B | 0.391820083 | 0.003451236 |
| ENSGALG00000010052 | PPP2R3C | 0.399540693 | 0.001962875 |
| ENSGALG00000015113 | PTAR1 | -0.539683505 | 0.001225948 |
| ENSGALG00000010053 | PTPRF | -0.480481292 | 0.003964241 |
| ENSGALG00000007155 | RMI2 | 1.140626082 | 0.001382943 |
| ENSGALG00000031018 | RNF165 | -1.03414841 | 0.001120092 |
| ENSGALG00000015311 | RNF38 | -0.537721584 | 0.003385081 |
| ENSGALG00000006486 | RPP30 | 0.342750725 | 0.004109447 |
| ENSGALG00000046226 | SCARB1 | 2.040797789 | 0.00121797 |
| ENSGALG00000004424 | SEC16B | -1.1085265 | 0.000492445 |
| ENSGALG00000037863 | SEC61G | 0.557099237 | 0.002778043 |
| ENSGALG00000042051 | SETD2 | -0.308714867 | 0.000307483 |
| ENSGALG00000004140 | SH3BP4 | -0.494833722 | 0.001195274 |
| ENSGALG00000001644 | SIN3A | -0.319985031 | 0.001157216 |
| ENSGALG00000002957 | SLC12A3 | -2.700635689 | 0.000223534 |
| ENSGALG00000010117 | SLC25A21 | 0.766964291 | 0.00238367 |
| ENSGALG00000015846 | SNAP91 | 1.1198235 | 0.000304383 |
| ENSGALG00000034528 | SNTB1 | 1.15258033 | 0.003458367 |
| ENSGALG00000036932 | SPEN | -0.388461063 | 0.00077178 |
| ENSGALG00000039497 | TFAP2E | -3.18357506 | 0.000779405 |
| ENSGALG00000015184 | TLE4Z1 | -0.444405062 | 0.001437148 |
| ENSGALG00000010896 | TMEM161B | -0.546018409 | 0.001173125 |
| ENSGALG00000001459 | TNNC1 | 1.720938851 | 0.003720707 |
| ENSGALG00000020523 | TOPORS | -0.473621698 | 0.003381281 |
| ENSGALG00000010152 | TSPAN8 | -3.77045907 | 0.002947966 |
| ENSGALG00000012259 | UBXN4 | 0.264129274 | 0.004330698 |
| ENSGALG00000043106 | WDR17 | -1.478943795 | 0.001766045 |
| ENSGALG00000016558 | VEGFD | 1.266960804 | 0.004105067 |
| ENSGALG00000011283 | ZNF385D | 1.483429288 | 0.004653997 |
| ENSGALG00000001518 | ZNF750 | -1.901269846 | 0.002582973 |

Supplementary Table S2

| | Fold Enrichment | p value |
|---|---|---|
| cytolysis by symbiont of host cells (GO:0001897) | > 100 | 1.44E-04 |
| hemolysis in other organism involved in symbiotic interaction (GO:0052331) | > 100 | 1.44E-04 |
| cytolysis in other organism involved in symbiotic interaction (GO:0051801) | > 100 | 2.30E-06 |
| | | |
| maintenance of mitochondrion location (GO:0051659) | > 100 | 1.44E-04 |
| | | |
| trans-synaptic signaling by trans-synaptic complex, modulating synaptic transmission (GO:0099557) | > 100 | 1.44E-04 |
| hemolysis in other organism (GO:0044179) | > 100 | 1.44E-04 |
| hemolysis by symbiont of host erythrocytes (GO:0019836) | > 100 | 1.44E-04 |
| killing of cells in other organism involved in symbiotic interaction (GO:0051883) | > 100 | 4.01E-06 |
| disruption of cells of other organism involved in symbiotic interaction (GO:0051818) | > 100 | 4.01E-06 |
| cytolysis in other organism (GO:0051715) | > 100 | 4.01E-06 |
| multi-organism cellular process (GO:0044764) | 60.51 | 3.21E-05 |
| cytolysis (GO:0019835) | 55.01 | 4.07E-05 |
| disruption of cells of other organism (GO:0044364) | 50.43 | 5.06E-05 |
| killing of cells of other organism (GO:0031640) | 50.43 | 5.06E-05 |
| axonal fasciculation (GO:0007413) | 40.34 | 8.99E-05 |
| neuron projection fasciculation (GO:0106030) | 40.34 | 8.99E-05 |
| | | |
| ephrin receptor signaling pathway (GO:0048013) | 26.03 | 2.58E-05 |
| positive regulation of phosphatidylinositol 3-kinase signaling (GO:0014068) | 17.17 | 1.16E-04 |
| | | |
| positive regulation of cellular protein localization (GO:1903829) | 7.55 | 4.91E-05 |
| regulation of cellular protein localization (GO:1903827) | 7.09 | 5.64E-07 |
| regulation of cellular localization (GO:0060341) | 4.52 | 1.54E-05 |
| | | |
| cell migration (GO:0016477) | 4.37 | 2.16E-05 |
| cell motility (GO:0048870) | 3.98 | 1.11E-04 |
| | | |
| regulation of protein localization (GO:0032880) | 3.94 | 5.84E-05 |
| | | |
| localization of cell (GO:0051674) | 3.94 | 5.84E-05 |
| locomotion (GO:0040011) | 3.73 | 2.39E-05 |
| | | |
| regulation of cell differentiation (GO:0045595) | 3.43 | 2.27E-06 |
| | | |
| regulation of response to stimulus (GO:0048583) | 3.01 | 1.48E-05 |
| | | |
| regulation of biological process (GO:0050789) | 2.61 | 3.94E-05 |
| regulation of cellular component organization (GO:0051128) | 2.57 | 4.79E-05 |
| regulation of multicellular organismal process (GO:0051239) | 2.55 | 1.41E-05 |
| positive regulation of cellular process (GO:0048522) | 2.33 | 1.37E-05 |
| positive regulation of biological process (GO:0048518) | 2.27 | 1.36E-05 |
| negative regulation of cellular process (GO:0048523) | 2.25 | 7.91E-05 |
| negative regulation of biological process (GO:0048519) | 2.09 | 5.55E-06 |
| cytolysis by symbiont of host cells (GO:0001897) | 2.06 | 2.05E-06 |
| | | |
| regulation of multicellular organismal development (GO:2000026) | 2.04 | 2.70E-05 |
| regulation of developmental process (GO:0050793) | 2.03 | 8.99E-05 |
| anatomical structure development (GO:0048856) | 2.02 | 6.47E-05 |
| multicellular organism development (GO:0007275) | 1.98 | 3.99E-05 |
| developmental process (GO:0032502) | 1.97 | 6.32E-05 |
| | | |
| positive regulation of metabolic process (GO:0009893) | 1.85 | 3.35E-05 |
| regulation of metabolic process (GO:0019222) | 1.47 | 1.21E-04 |
| positive regulation of cellular metabolic process (GO:0031325) | > 100 | 1.44E-04 |

| IF antibodies | | | | |
|---|---|---|---|---|
| **Primary Antibody** | **Species** | **Dilution** | **Source** | **Product #** |
| HNK1 | Mouse | 1:5 | Hybridoma bank | 3H5 |
| HIF-2α | Rabbit | 1:50 | Abcam | ab199 |
| SOX9 | Rabbit | 1:1000 | Millipore | ab5535 |
| | | | | |
| **Secondary Antibody** | **Species** | **Dilution** | **Source** | |
| Anti-Mouse Alexa Fluor-594 | Goat | 1:1000 | Invitrogen | A-11032 |
| Anti-Rabbit Alexa Fluor-546 | Donkey | 1:1000 / 1:500 | Invitrogen | A-10040 |
| Anti-Mouse Alexa Fluor-488 | Goat | 1:1000 | Invitrogen | A-11008 |

| IHC antibodies | | | | |
|---|---|---|---|---|
| **Primary Antibody** | **Species** | **Dilution** | **Source** | **Product #** |
| HIF-2α | Mouse | 1:1000 | Novus Biologicals | NB100-132 |
| HIF-2α | Rabbit | 1:4000 | Abcam | ab199 |
| TH | Rabbit | 1:1600 | Abcam | ab112 |

| In situ antibodies | | | | |
|---|---|---|---|---|
| | **Species** | **Dilution** | **Source** | **Product #** |
| Anti-dig-AP | Mouse | 1:2000 | Roche Diagnostics | 11093274910 |

| Nuclear staining | | | | |
|---|---|---|---|---|
| | **Species** | **Dilution** | **Source** | **Product #** |
| DAPI | | 1:3000 | Dako | D3571 |

| Western blot antibodies | | | | |
|---|---|---|---|---|
| **Primary Antibody** | **Species** | **Dilution** | **Source** | **Product #** |
| HIF-2α | Rabbit | 1:200 | Abcam | ab199 |
| SDHA | Mouse | 1:4000 | Abcam | ab14715 |
| | | | | |
| **Secondary Antibody** | **Species** | **Dilution** | **Source** | **Product #** |
| Anti-Rabbit | Monkey | 1:3000 | Invitrogen | 65-6120 |
| Anti-Mouse | Sheep | 1:5000 | Invitrogen | 62-6520 |

**AVIAN**

| Target gene | | 5' - 3' |
|---|---|---|
| *18S (Reference gene)* | Fwd | CCATGATTAAGAGGGACGGC |
| | Rev | TGGCAAATGCTTTCGCTTT |
| *28S (Reference gene)* | Fwd | GGTATGGGCCCGACGCT |
| | Rev | CCGATGCCGACGCTCAT |
| *EPAS1* | Fwd | GGCACCAATACCATGACGA |
| | Rev | CATGTGCGCGTAACTGTCC |
| *SOX10* | Fwd | AGCCAGCAATTGAGAAGAAGG |
| | Rev | GAGGTGCGAAGAGTTGTCC |
| *B3GAT1* | Fwd | TTGTGGAGGTGGTGAGGA |
| | Rev | GGCTGTAGGTGGGTGTAATG |
| *TFAP2B* | Fwd | CCCTCCAAAATCCGTTACTT |
| | Rev | GGGGACAGAGCAGAACACCT |
| *HOXC9* | Fwd | TAAGCCACGAAAACGAAGAG |
| | Rev | GAAGGAAAGTCGGCACAGTC |
| *HOXA2* | Fwd | AGGCAAGTGAAGGTCTGGTT |
| | Rev | TCGCCGTTCTGGTTCTCC |
| *NGFR* | Fwd | AGCAGGAGGAGGTGGAGAA |
| | Rev | CCCGTGTGAAGCAGTCTATG |
| *HES6* | Fwd | GCTGATGGCTGATTCCAAAG |
| | Rev | TCGCAGGTGAGGAGAAGGT |
| *AGPAT4* | Fwd | TGCTGGGCGTTCTAAATGG |
| | Rev | ACACTCCTGCTCATCTTCTGG |
| *HES5* | Fwd | GTATGCCTGGTGCCTCAAA |
| | Rev | GCTTGTGACCTCTGGAAATG |
| *RASL11B* | Fwd | GCTGGGCTGTGCTTTCTATG |
| | Rev | GGTGCTGGTGGTCTGTTGTT |
| *FMN2* | Fwd | CCATCAGCCAGTCAAGAGGA |
| | Rev | TAAAGCATCGGGAGCCAAAC |
| *TAGLN3* | Fwd | AGGCAGCATTTCCAGACC |
| | Rev | ATGGGTTCGTTTCCCTTTG |
| *NRCAM* | Fwd | TCATTCCGTGTGATTGCTGT |
| | Rev | AAGGATTTTCATCGGGGTTT |
| *EGFP* | Fwd | CCGACCACTACCAGCAGAAC |
| | Rev | TTGGGGTCTTTGCTCAGG |

**HUMAN**

| Target gene | | 5' - 3' |
|---|---|---|
| *UBC (Reference gene)* | Fwd | ATTTGGGTCGCGGTTCTTG |
| | Rev | TGCCTTGACATTCTCGATGGT |
| *YWHAZ (Reference gene)* | Fwd | ACTTTTGGTACATTGTGGCTTCAA |
| | Rev | CCGCCAGGACAAACCAGTAT |
| *SDHA (Reference gene)* | Fwd | TGGGAACAAGAGGGCATCTG |
| | Rev | CCACCACTGCATCAAATTCATG |
| *SOX10* | Fwd | GGGCAAGGTCAAGAAGGAG |
| | Rev | ACCAGCGTCCAGTCGTAG |
| *TFAP2B* | Fwd | ACGACCCCTACTCCCTGAAC |
| | Rev | TCCGAACCCACTTCTTGC |
| *HES6* | Fwd | ATGAGGACGGCTGGGAGA |
| | Rev | GCAGGCTCTCGTTGATCC |
| *AGPAT4* | Fwd | GCTCTTCACTCTCCTCCTCTG |
| | Rev | ACCACTCCAGCAGCATCAC |
| *HES5* | Fwd | TGGAGAAGGCCGACATCCT |
| | Rev | GGCGACGAAGGCTTTGC |
| *RASL11B* | Fwd | CGGTTCCTCACCAAACGA |
| | Rev | GGACCTGAATACCTGGAGTG |
| *FMN2* | Fwd | ATCCCTTCTGTGGTCTGCT |
| | Rev | AGTGTTCGTGGCTGGTTTG |
| *TAGLN3* | Fwd | GCAAATCTCCCAGTTCCTAAA |
| | Rev | TGTCCTTCCCTTCCCATAGA |
| *NRCAM* | Fwd | GCCATCCACCATACCATTTC |
| | Rev | ATCAAGGTCCCATCCTCTCC |

Table 1

A.

Stem cell associated genes

| Upstream Regulator | Molecule Type | p-value of overlap |
|---|---|---|
| SOX2 | transcription regulator | 3,72E-16 |
| POU5F1 / OCT4 | transcription regulator | 5,29E-16 |
| E2F4 | transcription regulator | 2,66E-12 |
| KLF4 | transcription regulator | 2,61E-11 |
| NANOG | transcription regulator | 2,81E-07 |
| EZH2 | transcription regulator | 2,69E-08 |
| GLI1 | transcription regulator | 1,68E-05 |
| NOTCH1 | transcription regulator | 2,31E-03 |
| KLF2 | transcription regulator | 3,00E-03 |
| SALL4 | transcription regulator | 1,67E-02 |
| HEY1 | transcription regulator | 1,97E-02 |
| KLF6 | transcription regulator | 2,66E-02 |
| HEY2 | transcription regulator | 3,57E-02 |
| BMI1 | transcription regulator | 2,84E-04 |

B.

BMP signaling associated genes

| Upstream Regulator | Molecule Type | p-value of overlap |
|---|---|---|
| BMP4 | growth factor | 5,74E-11 |
| BMP2 | growth factor | 2,69E-03 |
| BMP10 | growth factor | 5,06E-03 |
| BMP6 | growth factor | 1,17E-02 |
| SMAD2 | transcription regulator | 5,66E-09 |
| SMAD7 | transcription regulator | 8,82E-06 |
| SMAD4 | transcription regulator | 5,43E-05 |
| SMAD3 | transcription regulator | 1,38E-03 |

C.

Epithelial-to-Mesenchymal Transition (EMT) associated genes

| Upstream Regulator | Molecule Type | p-value of overlap |
|---|---|---|
| SNAI1 | transcription regulator | 8,22E-04 |
| ZEB2 | transcription regulator | 1,44E-03 |
| TWIST1 | transcription regulator | 3,00E-03 |
| ZEB1 | transcription regulator | 1,10E-02 |
| LEF1 | transcription regulator | 2,03E-02 |
| NODAL | growth factor | 2,13E-02 |